those receiving 7 mg or 14 mg of oral semaglutide (Ozempic pill, formerly known as Rybelsus, Novo Nordisk)
Lower concentrations allow for easier volume measurement when beginning therapy, while higher concentrations reduce injection volume as patients advance to maintenance doses
Some insurers who previously paid for the drugs are enacting new rules, requiring six months of documented lifestyle changes or a certain amount of weight loss for continued coverage
For those considering switching rather than stopping entirely, comparing options like switching from tirzepatide to semaglutide or using conversion charts to move between medications helps maintain continuity of care during transitions
Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial
however, a patient is often benefited from regular practice and gradual increment of exercise load